PE20011118A1 - (+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3h-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1h-quinolein-2-ona como compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto - Google Patents

(+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3h-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1h-quinolein-2-ona como compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto

Info

Publication number
PE20011118A1
PE20011118A1 PE2001000041A PE2001000041A PE20011118A1 PE 20011118 A1 PE20011118 A1 PE 20011118A1 PE 2001000041 A PE2001000041 A PE 2001000041A PE 2001000041 A PE2001000041 A PE 2001000041A PE 20011118 A1 PE20011118 A1 PE 20011118A1
Authority
PE
Peru
Prior art keywords
chloro
methyl
compound
alkyl
cyclopropylmetil
Prior art date
Application number
PE2001000041A
Other languages
English (en)
Inventor
Bingwei Vera Yang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20011118A1 publication Critical patent/PE20011118A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A (+)-6-[AMINO-(6-CLORO-PIRIDIN-3-IL)-(3-METIL-3H-IMIDAZOL-4-IL)-METIL]-4-(3-CLORO-FENIL)-1-CICLOPROPILMETIL-1H-QUINOLEIN-2-ONA. SE REFIERE TAMBIEN A UNA COMPOSICION QUE COMPRENDE ADEMAS AGENTE QUIMIOTERAPICO O INHIBIDORES DE METALOPROTEASA MMP2; INHIBIDORES DE MMP9, INHIBIDORES DE TRANSDUCCION DE SENALES, AGENTES ANTIPROLIFERATIVOS, AGENTES CAPACES DE BLOQUEAR CTL4; UN METODO PARA SEPARAR ENANTIOANMEROS (+) Y (-) DEL COMPUESTO DE FORMULA I DE LA MEZCLA RACEMICA, DONDE; R1 ES H, ALQUILO C1-C10; R2 ES HALO, CIANO, COOR15; R3 - R7 SON H, ALQUILO C1-C10, ALQUENILO C2-C10, ENTRE OTROS; Z ES HETEROCICLO AROMATICO DE 4-10 MIEMBROS; R9 ES -(CR13R14)t(IMIDAZOLILO), R9 ES (CR13R14)t(PIRIDINILO); R12 ES H, ALQUILO C1-C10, (CR13R14)t(CICLOALQUILO C3-C10), ENTRE OTROS; R13 Y R14 SON H, ALQUILO C1-C10; t ES 0-5; q ES 1-5; R15 NO ES H, R12; n ES 1-3 . UN METODO PARA SINTETIZAR ENANTIOMEROS (+), (-). EL COMPUESTO INHIBE FARNESIL TRANSFERASA ASI COMO EL DESARROLLO CELULAR ANORMAL Y PUEDE SER UTIL EN EL TRATAMIENTO DE CANCER DE PULMON, HUESO, PANCREAS, PIEL
PE2001000041A 2000-01-21 2001-01-17 (+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3h-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1h-quinolein-2-ona como compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto PE20011118A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17771800P 2000-01-21 2000-01-21

Publications (1)

Publication Number Publication Date
PE20011118A1 true PE20011118A1 (es) 2001-11-06

Family

ID=22649709

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000041A PE20011118A1 (es) 2000-01-21 2001-01-17 (+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3h-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1h-quinolein-2-ona como compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto

Country Status (17)

Country Link
US (1) US6479513B2 (es)
EP (1) EP1248782A1 (es)
JP (2) JP2003520796A (es)
AR (1) AR029792A1 (es)
AU (1) AU2001214087A1 (es)
BR (1) BR0016986A (es)
CA (1) CA2398353C (es)
CO (1) CO5271702A1 (es)
GT (1) GT200100008A (es)
HN (1) HN2000000266A (es)
MX (1) MXPA02007153A (es)
MY (1) MY126069A (es)
PA (1) PA8508101A1 (es)
PE (1) PE20011118A1 (es)
SV (1) SV2002000291A (es)
TN (1) TNSN01009A1 (es)
WO (1) WO2001053289A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
AU2002214056A1 (en) 2000-11-21 2002-06-03 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
WO2002051835A1 (en) 2000-12-27 2002-07-04 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
WO2003006006A1 (en) * 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
US7408063B2 (en) 2001-12-19 2008-08-05 Janssen Pharmaceutica, N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
ES2287466T3 (es) 2002-03-22 2007-12-16 Janssen Pharmaceutica N.V. Derivados de 2-quinolinona y quinazolina de bencilimidazolil sustituidas como inhibidores de la farnesil transferasa.
AU2003229688B2 (en) 2002-04-15 2009-07-30 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
DK1585743T3 (da) * 2002-12-19 2007-09-17 Pfizer 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme
JP2007530654A (ja) * 2004-03-30 2007-11-01 ファイザー・プロダクツ・インク シグナル伝達阻害剤の組合せ
CA2563805C (en) 2004-05-03 2012-11-13 Janssen Pharmaceutica N.V. Diastereoselective addition of lithiated n-methylimidazole on sulfinimines
WO2005105784A1 (en) * 2004-05-03 2005-11-10 Janssen Pharmaceutica N.V. Diastereoselective synthesis process for the preparation of imidazole compounds
WO2005105783A1 (en) * 2004-05-03 2005-11-10 Janssen Pharmaceutica N.V. Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline
AU2005276135B2 (en) * 2004-08-26 2011-04-28 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
DK1784396T3 (da) * 2004-08-26 2011-02-14 Pfizer Pyrazol-substituerede aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
CA2578075A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
EP1926996B1 (en) 2005-09-20 2011-11-09 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20070213366A1 (en) 2005-12-23 2007-09-13 Justman Craig J Treatment of Synucleinopathies
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
PL2056874T3 (pl) 2006-08-21 2013-02-28 Hoffmann La Roche Leczenie nowotworu przeciwciałem przeciw VEGF
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
NZ593090A (en) 2008-11-13 2013-06-28 Link Medicine Corp Azaquinolinone derivatives and uses thereof
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20110217309A1 (en) 2010-03-03 2011-09-08 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
EP3383375A1 (en) 2015-12-03 2018-10-10 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
ES2175137T3 (es) * 1995-12-08 2002-11-16 Janssen Pharmaceutica Nv Derivados de (imidazol-5-il)metil-2-quinolinona como inhibidores de laproteina farnesil-transferasa.
CN1314904A (zh) 1998-08-27 2001-09-26 辉瑞产品公司 用作抗癌剂的炔基取代的喹啉－2－酮衍生物
SK11002001A3 (sk) * 1999-02-11 2002-05-09 Pfizer Products Inc. Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.

Also Published As

Publication number Publication date
JP2003520796A (ja) 2003-07-08
AR029792A1 (es) 2003-07-16
CO5271702A1 (es) 2003-04-30
MY126069A (en) 2006-09-29
HN2000000266A (es) 2001-05-21
US6479513B2 (en) 2002-11-12
GT200100008A (es) 2001-10-19
PA8508101A1 (es) 2002-08-26
TNSN01009A1 (fr) 2005-11-10
CA2398353C (en) 2007-07-31
SV2002000291A (es) 2002-07-16
US20020004514A1 (en) 2002-01-10
MXPA02007153A (es) 2002-12-13
WO2001053289A1 (en) 2001-07-26
CA2398353A1 (en) 2001-07-26
AU2001214087A1 (en) 2001-07-31
EP1248782A1 (en) 2002-10-16
BR0016986A (pt) 2002-10-08
JP2007326868A (ja) 2007-12-20

Similar Documents

Publication Publication Date Title
PE20011118A1 (es) (+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3h-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1h-quinolein-2-ona como compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto
UY26391A1 (es) Inhibidores sglt2 de glucosidos de c-arilo y metodo
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
BR0200782A (pt) Compostos para o tratamento da isquemia
EP2325651A3 (en) Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
MY133996A (en) Compounds for the treatment of ischemia
AP9901478A0 (en) Compounds for the treatment of ischemia.
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
BR0215405A (pt) Composições e processos de uso de collajolie
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
RS20050311A (en) Selected cgrp antagonists,method for production and use thereof as medicament
AR051446A1 (es) Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
EP1590336A4 (en) SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
MX2007006397A (es) Derivados de tetrahidropirano.
MXPA02005173A (es) Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.
EP1208129A1 (en) DERIVATIVE POLYURETHANE COMPOSITIONS AND THEIR METHODS OF MANUFACTURING
WO2003105767A8 (en) ANTIFUNGAL PARENTERAL PRODUCTS
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
CA2334257A1 (en) Treatment of osteoporosis with ep2/ep4 receptor selective agonists
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
AR032872A1 (es) Composicion para aclarar la piel y el metodo de aplicacion
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
EP1667976A4 (en) Isoquinolinone POTASSIUM CHANNEL INHIBITORS
WO2005060960A3 (en) Use of histamine to treat bone disease

Legal Events

Date Code Title Description
FD Application declared void or lapsed